Your browser doesn't support javascript.
loading
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Hailemichael, Yared; Johnson, Daniel H; Abdel-Wahab, Noha; Foo, Wai Chin; Bentebibel, Salah-Eddine; Daher, May; Haymaker, Cara; Wani, Khalida; Saberian, Chantal; Ogata, Dai; Kim, Sang T; Nurieva, Roza; Lazar, Alexander J; Abu-Sbeih, Hamzah; Fa'ak, Faisal; Mathew, Antony; Wang, Yinghong; Falohun, Adewunmi; Trinh, Van; Zobniw, Chrystia; Spillson, Christine; Burks, Jared K; Awiwi, Muhammad; Elsayes, Khaled; Soto, Luisa Solis; Melendez, Brenda D; Davies, Michael A; Wargo, Jennifer; Curry, Jonathan; Yee, Cassian; Lizee, Gregory; Singh, Shalini; Sharma, Padmanee; Allison, James P; Hwu, Patrick; Ekmekcioglu, Suhendan; Diab, Adi.
Affiliation
  • Hailemichael Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Johnson DH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Precision Cancer Therapies Program, Department of Hematology and Medical Oncology, Ochsner Health, New Orleans, LA, USA.
  • Abdel-Wahab N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Rheumatology and Rehabilitation, Assiut University Hospi
  • Foo WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Daher M; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Saberian C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ogata D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kim ST; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nurieva R; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA.
  • Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houst
  • Abu-Sbeih H; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fa'ak F; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mathew A; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang Y; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Falohun A; Section of Rheumatology & Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Trinh V; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zobniw C; Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Spillson C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Burks JK; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Awiwi M; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Elsayes K; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Soto LS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Melendez BD; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wargo J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Curry J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lizee G; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Singh S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ekmekcioglu S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: adiab@mdanderson.org.
Cancer Cell ; 40(5): 509-523.e6, 2022 05 09.
Article in En | MEDLINE | ID: mdl-35537412
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colitis / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colitis / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos